Notably, SS subtype III had overexpression of inhibitory immune checkpoints which can be targeted with checkpoint inhibitors (i.e., PDCD1 (PD‐1) and CD274 (PD‐L1)) (P = 6.5e‐05 and P = 0.009, respectively) as displayed in Figure 4d–f. This evidence concerns the gene CD274 and synovial sarcoma.